<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002047'>Malignant hyperthermia</z:hpo> (MH) is an inherited disorder of the skeletal muscles that can be triggered by many <z:chebi fb="0" ids="38867">anesthetic agents</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>MH has different presentations and manifestations that makes it difficult to diagnose </plain></SENT>
<SENT sid="2" pm="."><plain>Patients with laminin alpha2 deficiency have never been reported to be susceptible to MH </plain></SENT>
<SENT sid="3" pm="."><plain>We present a suspected MH episode in the absence of classic triggering agents in a 7-year-old boy with laminin alpha2 (merosin) deficiency and <z:hpo ids='HP_0003741'>congenital muscular dystrophy</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The episode was diagnosed using the MH clinical grading scale and responded well to prompt management with dantrolene </plain></SENT>
<SENT sid="5" pm="."><plain>We conclude that patients with laminin alpha2 deficiency may be susceptible to MH, and early suspicion and rapid treatment is vital in the management of MH </plain></SENT>
<SENT sid="6" pm="."><plain>Anesthesiologists should be prepared to treat MH in susceptible patients even in the absence of a classical triggering agent </plain></SENT>
</text></document>